150 related articles for article (PubMed ID: 28720688)
1. Primary immune thrombocytopenia in adults: clinical practice versus management guidelines.
Ng T; Gatt A; Smith M
Postgrad Med J; 2017 Nov; 93(1105):645-646. PubMed ID: 28720688
[No Abstract] [Full Text] [Related]
2. Thrombopoietin-receptor agonists for primary immune thrombocytopenia.
Imbach P; Crowther M
N Engl J Med; 2011 Aug; 365(8):734-41. PubMed ID: 21864167
[No Abstract] [Full Text] [Related]
3. Thrombopoietin-receptor agonists for immune thrombocytopenia.
Jansen AJ; Swart RM; te Boekhorst PA
N Engl J Med; 2011 Dec; 365(23):2240-1. PubMed ID: 22150056
[No Abstract] [Full Text] [Related]
4. Treating chemotherapy-induced thrombocytopenia: is it time for oncologists to use thrombopoietin agonists?
Hassan MN; Waller EK
Oncology (Williston Park); 2015 Apr; 29(4):295-6. PubMed ID: 25952493
[No Abstract] [Full Text] [Related]
5. Thrombocytopenia: optimizing approaches in cancer patients.
Piatek C; Akhtari M
Oncology (Williston Park); 2015 Apr; 29(4):297-8. PubMed ID: 25952494
[No Abstract] [Full Text] [Related]
6. Simultaneous romiplostin, eltrombopag, and prednisone were successful in severe thrombocytopenia of Evans syndrome refractory to hydrocortisone, splenectomy, intravenous IgG, and rituximab.
Ruiz-Arguelles GJ; Ruiz-Delgado GJ; Velázquez-Sánchez-de-Cima S; Zamora-Ortiz G
Hematology; 2013 May; 18(3):175-7. PubMed ID: 23321502
[TBL] [Abstract][Full Text] [Related]
7. Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role of MPL polymorphisms.
Polverelli N; Palandri F; Iacobucci I; Catani L; Martinelli G; Vianelli N
Br J Haematol; 2013 Apr; 161(1):142-4. PubMed ID: 23278214
[No Abstract] [Full Text] [Related]
8. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R
Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388
[TBL] [Abstract][Full Text] [Related]
9. [New treatment options for primary immune thrombocytopenia].
Gudbrandsdottir S; Frederiksen H; Birgens HS; Nielsen CH; Nielsen OJ; Stentoft J; Hasselbalch HC
Ugeskr Laeger; 2011 Jan; 173(4):271-4. PubMed ID: 21262171
[TBL] [Abstract][Full Text] [Related]
10. Immune thrombocytopenia during childhood: new approaches to classification and management.
Buchanan GR
J Pediatr; 2014 Sep; 165(3):437-9. PubMed ID: 24973290
[No Abstract] [Full Text] [Related]
11. New therapeutic options for immune thrombocytopenia.
Schipperus M; Fijnheer R
Neth J Med; 2011; 69(11):480-5. PubMed ID: 22173361
[TBL] [Abstract][Full Text] [Related]
12. Thrombopoietin receptor agonists in the treatment of immune thrombocytopenia: a clinician's perspective.
Ruggeri M
Am J Hematol; 2012 Oct; 87(10):946-7. PubMed ID: 22847498
[No Abstract] [Full Text] [Related]
13. The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study.
Mahévas M; Fain O; Ebbo M; Roudot-Thoraval F; Limal N; Khellaf M; Schleinitz N; Bierling P; Languille L; Godeau B; Michel M
Br J Haematol; 2014 Jun; 165(6):865-9. PubMed ID: 24725224
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of thrombopoietin-receptor agonists in the treatment of refractory immune thrombocytopenia associated to systemic lupus erythematosus.
Magnano L; Enríquez H; Esteve J; Cervera R; Espinosa G
J Rheumatol; 2014 Sep; 41(9):1895-6. PubMed ID: 25179983
[No Abstract] [Full Text] [Related]
15. Clinical outcomes in eight patients with immune thrombocytopenia each treated with the three approved thrombopoietin receptor agonists.
Lee EJ; Seshadri M; Bussel JB
Am J Hematol; 2021 Oct; 96(10):E373-E376. PubMed ID: 34152624
[No Abstract] [Full Text] [Related]
16. Sequential treatment with thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): experience in our center.
González KJ; Zuluaga SO; DaRos CV; Rodríguez PP; Martí AC
Ann Hematol; 2017 Mar; 96(3):507-508. PubMed ID: 27975127
[No Abstract] [Full Text] [Related]
17. Current status of thrombopoietic agents.
Rhodes E; Stasi R
Expert Rev Hematol; 2010 Apr; 3(2):217-25. PubMed ID: 21083464
[TBL] [Abstract][Full Text] [Related]
18. [Diagnosis and therapy of autoimmune thrombocytopenia. Recommendations of a joint Expert Group of DGHO, DGTI, DTH].
Matzdorff A; Giagounidis A; Greinacher A; Hiller E; Kiefel V; Müller-Beissenhirtz H; Ostermann H; Rummel M; Sachs UJ; Salama A
Onkologie; 2010; 33 Suppl 3():2-20. PubMed ID: 20484949
[No Abstract] [Full Text] [Related]
19. [Trombopag for chronic immune thrombocytopenia in a patient previously treated with romiplostim].
Rodríguez Vargas B; Serna Pérez J; Bermejo Vicedo T
Farm Hosp; 2013; 37(3):265-6. PubMed ID: 23789804
[No Abstract] [Full Text] [Related]
20. Thrombopoietin receptor agonists in immune thrombocytopenia of less than 6 months duration.
Arumugaswamy A; He S; Quach H; Brotchie J; Grigg A
Intern Med J; 2014 May; 44(5):519-21. PubMed ID: 24816314
[No Abstract] [Full Text] [Related]
[Next] [New Search]
